Suppr超能文献

恰加斯病与 SARS-CoV-2 合并感染不会导致住院结局恶化。

Chagas disease and SARS-CoV-2 coinfection does not lead to worse in-hospital outcomes.

机构信息

PROSICS Barcelona, Vall d'Hebron University Hospital, Passeig de la Vall d'Hebron, 119, 08035, Barcelona, Spain.

Instituto René Rachou-FIOCRUZ Minas, Av. Augusto de Lima, 1715, Belo Horizonte, Brazil.

出版信息

Sci Rep. 2021 Oct 13;11(1):20289. doi: 10.1038/s41598-021-96825-3.

Abstract

Chagas disease (CD) continues to be a major public health burden in Latina America. Information on the interplay between COVID-19 and CD is lacking. Our aim was to assess clinical characteristics and in-hospital outcomes of patients with CD and COVID-19, and to compare it to non-CD patients. Consecutive patients with confirmed COVID-19 were included from March to September 2020. Genetic matching for sex, age, hypertension, diabetes mellitus and hospital was performed in a 4:1 ratio. Of the 7018 patients who had confirmed COVID-19, 31 patients with CD and 124 matched controls were included (median age 72 (64-80) years-old, 44.5% were male). At baseline, heart failure (25.8% vs. 9.7%) and atrial fibrillation (29.0% vs. 5.6%) were more frequent in CD patients than in the controls (p < 0.05). C-reactive protein levels were lower in CD patients compared with the controls (55.5 [35.7, 85.0] vs. 94.3 [50.7, 167.5] mg/dL). In-hospital management, outcomes and complications were similar between the groups. In this large Brazilian COVID-19 Registry, CD patients had a higher prevalence of atrial fibrillation and chronic heart failure compared with non-CD controls, with no differences in-hospital outcomes. The lower C-reactive protein levels in CD patients require further investigation.

摘要

恰加斯病(CD)仍然是拉丁美洲的一个主要公共卫生负担。关于 COVID-19 和 CD 之间相互作用的信息尚不清楚。我们的目的是评估患有 CD 和 COVID-19 的患者的临床特征和住院结局,并将其与非 CD 患者进行比较。连续纳入 2020 年 3 月至 9 月期间确诊的 COVID-19 患者。以性别、年龄、高血压、糖尿病和医院为基础,对 CD 患者和 COVID-19 患者进行 4:1 的遗传匹配。在 7018 例确诊 COVID-19 的患者中,纳入了 31 例 CD 患者和 124 例匹配对照(中位年龄 72(64-80)岁,44.5%为男性)。在基线时,心力衰竭(25.8%比 9.7%)和心房颤动(29.0%比 5.6%)在 CD 患者中比对照组更常见(p<0.05)。与对照组相比,CD 患者的 C 反应蛋白水平较低(55.5[35.7,85.0]比 94.3[50.7,167.5]mg/dL)。两组之间的住院管理、结局和并发症相似。在这项大型巴西 COVID-19 登记研究中,与非 CD 对照组相比,CD 患者心房颤动和慢性心力衰竭的患病率更高,但住院结局无差异。CD 患者较低的 C 反应蛋白水平需要进一步研究。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2fa3/8514447/52497523ae89/41598_2021_96825_Fig1_HTML.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验